Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Equity (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Return on Equity for 10 consecutive years, with 0.27% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 23.0% year-over-year to 0.27%, compared with a TTM value of 0.27% through Dec 2025, up 23.0%, and an annual FY2025 reading of 0.25%, up 34.0% over the prior year.
  • Return on Equity was 0.27% for Q4 2025 at Spyre Therapeutics, up from 0.33% in the prior quarter.
  • Across five years, Return on Equity topped out at 11.04% in Q4 2023 and bottomed at 2.17% in Q1 2024.
  • Average Return on Equity over 5 years is 0.05%, with a median of 0.61% recorded in 2021.
  • The sharpest move saw Return on Equity surged 1246bps in 2023, then crashed -1153bps in 2024.
  • Year by year, Return on Equity stood at 0.71% in 2021, then crashed by -101bps to 1.42% in 2022, then surged by 876bps to 11.04% in 2023, then crashed by -104bps to 0.49% in 2024, then surged by 46bps to 0.27% in 2025.
  • Business Quant data shows Return on Equity for SYRE at 0.27% in Q4 2025, 0.33% in Q3 2025, and 0.44% in Q2 2025.